secwatch.observer — SEC 8-K summary
======================================

Issuer:     HERON THERAPEUTICS, INC. /DE/ (HRTX)
CIK:        0000818033
Form:       8-K
Filed at:   2025-05-06T23:59:59+00:00
Accession:  0000950170-25-063967
Event type: litigation
Sentiment:  neutral
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Heron settles patent litigation with Mylan, grants generic license for CINVANTI/APONVIE starting June 2032
--------------------------------------------------------------------------------

- Settlement resolves patent litigations in U.S. District Court for Delaware initiated in Sep 2023 and Jan 2024.
- Heron grants Mylan a license to market generic CINVANTI and APONVIE beginning June 1, 2032 (or earlier under certain circumstances).
- Patent protection for CINVANTI and APONVIE extends to 2035; license starts ~3 years before expiration.
- Parties will file stipulation to dismiss pending litigations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/818033/000095017025063967/0000950170-25-063967-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/818033/000095017025063967/hrtx-20250506.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-063967

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer